Dr. Mahant to assist with the development of screening criteria to identify patients who are most likely to receive clinical benefit from the ValloVax immunotherapy.
Today, Batu Biologics announced the release of the Starve The Tumor Video Blog, a series of informational videos and articles designed to provide background information on our lead therapeutic ValloVax.
Batu Biologics, a clinical stage immuno-oncology Company, announced today the filing of a patent application covering methods of selecting patients likely to respond to ValloVax.
Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try Law.
Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board.
Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareholders of the Company, providing a comprehensive update on the clinical progress of the ValloVax immune therapy.
Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco Marincola as the Chairman of the Company’s Clinical Advisory Board.
Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally renowned panel of biotechnology companies focusing on immunotherapy.
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology.
Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.